Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glucose Intolerance
Conditions
Glucose Intolerance
Trial Timeline
Aug 16, 2011 → Apr 9, 2012
NCT ID
NCT01405911About Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg
Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg is a phase 2 stage product being developed by Merck for Glucose Intolerance. The current trial status is completed. This product is registered under clinical trial identifier NCT01405911. Target conditions include Glucose Intolerance.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01405911 | Phase 2 | Completed |
Competing Products
17 competing products in Glucose Intolerance
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin + Alpha lipoic acid + Olmesartan + Placebo | Daiichi Sankyo | Pre-clinical | 23 |
| Exenatide + Metformin | Eli Lilly | Approved | 85 |
| AZD1656 | AstraZeneca | Phase 1 | 33 |
| Candesartan + Placebo | AstraZeneca | Approved | 85 |
| Sitagliptin-Metformin + Metformin + Placebo pill | Merck | Approved | 85 |
| Comparator: exenatide + Comparator: exenatide + Comparator: Placebo | Merck | Phase 1 | 33 |
| Placebo + Januvia | Merck | Phase 2 | 52 |
| cyclosporine micro-emulsion | Novartis | Approved | 85 |
| Ramipril + Rosiglitazone | Pfizer | Phase 3 | 76 |
| HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |
| UX007 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| UX007 + Placebo | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| UX007 + Placebo | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| GFT505 80mg + Placebo | Genfit | Phase 2 | 44 |